Drop to Gate Nasal Drops Attenuates Sepsis‐Induced Cognitive Dysfunction

Nasal administration can bypass the blood‐brain barrier and directly deliver drugs to the brain, providing a non‐invasive route for central nervous system (CNS) diseases. Inspired by the appearance that a gate can block the outside world and the characteristics of the sol–gel transition can form a “gate” in the nasal cavity, a Drop to Gate nasal drop (DGND) is designed to set a gate in nose, which achieves protecting role from the influence of nasal environment. The DGND demonstrates the efficiency and application prospect of delivering drugs to the brain through the N‐to‐B. The effective concentration of single administration is increased through the hydrophobic interaction between C8‐GelMA and SRT1720 (SA), and then cross‐linked under UV to form nanogel, which can respond to MMP in the inflammatory microenvironment of sepsis‐induced cognitive dysfunction. Finally, the SA/nanogel is compounded into the thermogel, which can respond to the nasal cavity temperature to form DGND in situ, increasing the residence time and delivery efficiency of drugs in the nasal cavity. In vitro, the DGND alleviates lipopolysaccharides (LPS)‐induced BV2 inflammation. In vivo, DGND effectively targets the nasal mucosa and deliver drugs to the brain, which activate Sirt1 to alleviate inflammation mediated by microglia and improve cognitive dysfunction in sepsis mice. A Drop to Gate nasal drops (DGND) inspired by the appearance that a gate can block the outside world and the characteristic of the sol–gel transition can form a “gate” structure in the nasal cavity is developed in this article. It demonstrates the effectiveness and application prospects of delivering drugs to the brain through the N‐to‐B pathway to attenuate sepsis‐induced cognitive dysfunction.